Oova Company Profile

Background

Founded in 2017, Oova is a New York-based women's health company specializing in at-home hormone monitoring solutions. The company's mission is to empower women by providing personalized, data-driven insights into their reproductive health, thereby facilitating informed decisions throughout various life stages. Oova's flagship product, the Oova Kit, enables users to track key fertility hormones—luteinizing hormone (LH) and progesterone—through non-invasive urine tests, offering real-time analytics and actionable recommendations.

Key Strategic Focus

Oova's strategic focus centers on revolutionizing women's reproductive health through innovative, user-friendly diagnostic tools. By integrating advanced biochemistry with artificial intelligence, the company aims to provide accurate, at-home hormone monitoring solutions that cater to individual health profiles. Initially targeting fertility tracking, Oova plans to expand its offerings to address other aspects of women's health, including perimenopause and chronic disease management.

Financials and Funding

Oova has successfully secured funding to support its growth and product development:

Seed Funding (July 2021): Raised $1.2 million led by BBG Ventures, facilitating the official launch of the Oova Kit.

Series A Funding (June 2023): Secured $10.3 million in a round led by Spero Ventures, with participation from US Fertility, Virgin Group, Jefferson Health, Connecticut Innovations, and notable individuals such as Sara Blakely and Hannah Bronfman. This capital is intended to expand testing capabilities and explore applications in other phases of women's health.

Pipeline Development

Oova's primary product, the Oova Kit, is an FDA-registered at-home urine test that measures LH and progesterone levels to identify fertile days and confirm ovulation. Since its launch in 2021, the kit has monitored over 10,000 cycles, enhancing its predictive accuracy. The company is developing additional features, including the measurement of estrogen levels, to provide a more comprehensive fertility profile. Future plans involve expanding into other areas of women's health, such as perimenopause and chronic disease management.

Technological Platform and Innovation

Oova distinguishes itself through its proprietary technological platform that combines advanced biochemistry with machine learning algorithms:

Proprietary Technologies: The Oova Kit utilizes innovative biochemistry to detect and quantify hormone levels in urine samples accurately.

Scientific Methods: The platform employs machine learning algorithms to interpret hormone data, providing personalized insights and recommendations based on individual hormone patterns.

Leadership Team

Oova's leadership comprises experienced professionals dedicated to advancing women's health:

Amy Divaraniya, Ph.D. – Founder and CEO: With a background in biomedical sciences and genetics, Dr. Divaraniya founded Oova to address gaps in fertility tracking and women's health diagnostics.

Jerome Scelza – Co-Founder and CTO: Leads the technological development of Oova's products, integrating biochemistry with artificial intelligence to create user-friendly diagnostic tools.

Competitor Profile

Market Insights and Dynamics

The global fertility technology market was valued at $33.1 billion in 2020 and is projected to reach $47.9 billion by 2027. This growth is driven by increasing awareness and demand for accessible fertility solutions.

Competitor Analysis

Oova operates in a competitive landscape with several key players:

Mira: Offers at-home fertility tracking devices that measure hormone levels to predict ovulation.

Proov: Provides at-home tests to confirm ovulation by detecting progesterone metabolites.

Inne: Develops biotechnology solutions for contraception and fertility monitoring.

Hertility Health: Offers reproductive health solutions, including hormone testing and fertility assessments.

These competitors focus on various aspects of fertility tracking and women's health, utilizing different technologies and methodologies.

Strategic Collaborations and Partnerships

Oova has established significant partnerships to enhance its market position and product offerings:

Thorne Research (2019): Collaborated to pilot Oova's fertility monitoring tool, making it available to Thorne's extensive network of customers and clinicians.

Markacy (2023): Partnered with the digital strategy firm to scale Oova's B2C and B2B businesses.

Operational Insights

Oova's strategic considerations include:

Market Position: Differentiating itself through the integration of biochemistry and AI to provide personalized, at-home hormone monitoring solutions.

Competitive Advantages: Offering a comprehensive fertility tracking solution that measures multiple hormones and provides real-time analytics, setting it apart from competitors focusing on single-hormone detection.

Strategic Opportunities and Future Directions

Oova's strategic roadmap includes:

Product Expansion: Developing additional hormone tests, such as estrogen measurement, to provide a more comprehensive fertility profile.

Market Diversification: Extending product offerings to address other aspects of women's health, including perimenopause and chronic disease management.